The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
The cytokine interleukin-1[beta] (IL-1[beta]) is known to stimulate proinflammatory immune responses and impair [beta]-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1[beta] receptor antagonist,...
Gespeichert in:
| Veröffentlicht in: | Journal of Diabetes Research 2016-01, Vol.2016 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Journal of Diabetes Research |
| container_volume | 2016 |
| creator | Cucak, Helena Hansen, Gitte Vrang, Niels Skarsfeld, Torben Steiness Eva Jelsing, Jacob |
| description | The cytokine interleukin-1[beta] (IL-1[beta]) is known to stimulate proinflammatory immune responses and impair [beta]-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1[beta] receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1[beta] activated pathways. |
| doi_str_mv | 10.1155/2016/7484601 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A512375115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A512375115</galeid><sourcerecordid>A512375115</sourcerecordid><originalsourceid>FETCH-LOGICAL-g985-25ba24f728340966b086dcf731880e627c0faaf32738597cb64c42a421bc163f3</originalsourceid><addsrcrecordid>eNptkE9rAjEQxXNooWK99QMECr2t5n_Wo1htBVuL3Vspko0TTVkTMen3b6AeLJQ5DLx5v-HNIHRHyZBSKUeMUDXSohaK0CvUY5yKSmkhb9AgJd8SSTTnktMe-mr2gBfLin60kM0nXoOFY44nPAnZ7GLwKeP32ZoKgt9iyscYIOFcmFVIkHF0-NGbghbVBzyHg-kAv8YQW0hwnnmLX7yFW3TtTJdgcO591MxnzfS5Wq6eFtPJstqNa1kx2RomnGY1F2SsVEtqtbVOc1rXBBTTljhjHGea13KsbauEFcwIRltLFXe8j-5_1-5KlI0PLuaTsQef7GYiKeNalhcV1_AfV6ktHLwtVzpf9D_AwwWwB9PlfYrdd_YxpEvjD5TAcVI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice</title><source>Alma/SFX Local Collection</source><creator>Cucak, Helena ; Hansen, Gitte ; Vrang, Niels ; Skarsfeld, Torben ; Steiness Eva ; Jelsing, Jacob</creator><creatorcontrib>Cucak, Helena ; Hansen, Gitte ; Vrang, Niels ; Skarsfeld, Torben ; Steiness Eva ; Jelsing, Jacob</creatorcontrib><description>The cytokine interleukin-1[beta] (IL-1[beta]) is known to stimulate proinflammatory immune responses and impair [beta]-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1[beta] receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1[beta] activated pathways.</description><identifier>ISSN: 2314-6745</identifier><identifier>DOI: 10.1155/2016/7484601</identifier><language>eng</language><publisher>John Wiley & Sons, Inc</publisher><subject>Blood sugar ; Comparative analysis ; Diabetes therapy ; Disease susceptibility ; Immune response ; Immunotherapy ; Interleukins ; Type 1 diabetes</subject><ispartof>Journal of Diabetes Research, 2016-01, Vol.2016</ispartof><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Cucak, Helena</creatorcontrib><creatorcontrib>Hansen, Gitte</creatorcontrib><creatorcontrib>Vrang, Niels</creatorcontrib><creatorcontrib>Skarsfeld, Torben</creatorcontrib><creatorcontrib>Steiness Eva</creatorcontrib><creatorcontrib>Jelsing, Jacob</creatorcontrib><title>The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice</title><title>Journal of Diabetes Research</title><description>The cytokine interleukin-1[beta] (IL-1[beta]) is known to stimulate proinflammatory immune responses and impair [beta]-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1[beta] receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1[beta] activated pathways.</description><subject>Blood sugar</subject><subject>Comparative analysis</subject><subject>Diabetes therapy</subject><subject>Disease susceptibility</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Interleukins</subject><subject>Type 1 diabetes</subject><issn>2314-6745</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkE9rAjEQxXNooWK99QMECr2t5n_Wo1htBVuL3Vspko0TTVkTMen3b6AeLJQ5DLx5v-HNIHRHyZBSKUeMUDXSohaK0CvUY5yKSmkhb9AgJd8SSTTnktMe-mr2gBfLin60kM0nXoOFY44nPAnZ7GLwKeP32ZoKgt9iyscYIOFcmFVIkHF0-NGbghbVBzyHg-kAv8YQW0hwnnmLX7yFW3TtTJdgcO591MxnzfS5Wq6eFtPJstqNa1kx2RomnGY1F2SsVEtqtbVOc1rXBBTTljhjHGea13KsbauEFcwIRltLFXe8j-5_1-5KlI0PLuaTsQef7GYiKeNalhcV1_AfV6ktHLwtVzpf9D_AwwWwB9PlfYrdd_YxpEvjD5TAcVI</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Cucak, Helena</creator><creator>Hansen, Gitte</creator><creator>Vrang, Niels</creator><creator>Skarsfeld, Torben</creator><creator>Steiness Eva</creator><creator>Jelsing, Jacob</creator><general>John Wiley & Sons, Inc</general><scope/></search><sort><creationdate>20160101</creationdate><title>The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice</title><author>Cucak, Helena ; Hansen, Gitte ; Vrang, Niels ; Skarsfeld, Torben ; Steiness Eva ; Jelsing, Jacob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g985-25ba24f728340966b086dcf731880e627c0faaf32738597cb64c42a421bc163f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Blood sugar</topic><topic>Comparative analysis</topic><topic>Diabetes therapy</topic><topic>Disease susceptibility</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Interleukins</topic><topic>Type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cucak, Helena</creatorcontrib><creatorcontrib>Hansen, Gitte</creatorcontrib><creatorcontrib>Vrang, Niels</creatorcontrib><creatorcontrib>Skarsfeld, Torben</creatorcontrib><creatorcontrib>Steiness Eva</creatorcontrib><creatorcontrib>Jelsing, Jacob</creatorcontrib><jtitle>Journal of Diabetes Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cucak, Helena</au><au>Hansen, Gitte</au><au>Vrang, Niels</au><au>Skarsfeld, Torben</au><au>Steiness Eva</au><au>Jelsing, Jacob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice</atitle><jtitle>Journal of Diabetes Research</jtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issn>2314-6745</issn><abstract>The cytokine interleukin-1[beta] (IL-1[beta]) is known to stimulate proinflammatory immune responses and impair [beta]-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1[beta] receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1[beta] activated pathways.</abstract><pub>John Wiley & Sons, Inc</pub><doi>10.1155/2016/7484601</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6745 |
| ispartof | Journal of Diabetes Research, 2016-01, Vol.2016 |
| issn | 2314-6745 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A512375115 |
| source | Alma/SFX Local Collection |
| subjects | Blood sugar Comparative analysis Diabetes therapy Disease susceptibility Immune response Immunotherapy Interleukins Type 1 diabetes |
| title | The IL-1[beta] Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A45%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20IL-1%5Bbeta%5D%20Receptor%20Antagonist%20SER140%20Postpones%20the%20Onset%20of%20Diabetes%20in%20Female%20Nonobese%20Diabetic%20Mice&rft.jtitle=Journal%20of%20Diabetes%20Research&rft.au=Cucak,%20Helena&rft.date=2016-01-01&rft.volume=2016&rft.issn=2314-6745&rft_id=info:doi/10.1155/2016/7484601&rft_dat=%3Cgale%3EA512375115%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A512375115&rfr_iscdi=true |